LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Dexcom G7 15 Day arrives in Canada in November with longer sensor wear and expanded insurance coverage. Here's what users ...
The upcoming system, for people with Type 1 or Type 2 diabetes ages 18 and up, boosts wear time by 50% over the currently available G7 sensor. (Dexcom) Dexcom has won a clearance from the FDA for its ...
DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read why DXCM stock is a Buy.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom said that its glucose data can also be viewed alongside other health information collected by the Apple Watch—such as physical activity, sleep and other factors that can affect blood sugar ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It’s the longest-lasting wearable on the market. The G7 15 ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results